The pharmaceutical sector continues to offer opportunities. Business Today TV's Shailendra Bhatnagar discussed with Vaibhav ...

The FDA has approved a new drug called Revlimid to treat a type of the rare blood disorder, myelodysplastic syndrome (MDS), which can progress to become leukemia. Revlimid treats a type of MDS ...

Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...

Revlimid (lenalidomide) is a brand-name drug that doctors may prescribe to treat certain cancers of the blood. If a person has a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) ...

Doctors prescribe Revlimid (lenalidomide) to treat certain blood cancers, including multiple myeloma, mantle cell lymphoma, and others. The drug is not safe to take while pregnant, and doctors avoid ...

Maintenance Revlimid was shown to improve overall survival in patients with multiple myeloma. Patients with multiple myeloma saw a 26 percent decrease in risk of death when they took maintenance ...

The combination of Revlimid with dexamethasone, previously approved for treatment in patients with multiple myeloma who received at least 1 prior treatment, has received FDA approval for use in newly ...

BOSTON, June 6 (Reuters) - Two major studies of Celgene Corp's multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem-cell transplantation it reduced the risk of ...

On May 7, 2015, the European Patent Office (EPO) revoked one of Celgene's ( CELG) patents on Revlimid®. Revlimid® reportedly accounts for almost $5 billion of Celgene's nearly $7.5 billion in annual ...